P3 Health Partners
Closed (deSPAC)Health Care · population health management and value-based primary care
- What it is
- Health Partners (NASDAQ: PIII): P3 Health Partners Inc
- What it’s doing now
- Merging with Foresight Acquisition Corp. (FORE) — closed (despac).
- What you should know
- Data is still being assembled for this company — what is shown below is everything we have verified so far.
The business, per its filings
SEC primaryHealth Partners (NASDAQ: PIII): P3 Health Partners Inc. is a leading population health management company committed to transforming healthcare by improving the lives of both patients and providers. Founded and led by physicians, P3 has an expansive network of more than 2,500 affiliated primary care providers across the country. Our local teams of health care professionals manage the care of thousands of patients in 18 counties across five states. P3 supports primary care providers with value-based care coordination and administrative services that improve patient outcomes and lower costs. Through partnerships with these local providers, the P3 care team creates an enhanced patient experience by navigating, coordinating, and integrating the patient’s care within the healthcare system. For more information, visit www.p3hp.org and follow us on @p3healthpartners and Facebook.com/p3healthpartners.
Source: 8-K, accession 0001832511-26-000032
What the company says about itself
Web research — not auditedP3 Health Partners is a population health management company that supports providers with administrative services and care coordination for Medicare Advantage patients. Founded and led by physicians, P3's model aggregates and supports existing healthcare resources to build a network of community providers delivering coordinated, integrated care focused on wellness, prevention, and improved patient outcomes.
- Markets:
- Population health management | Healthcare | Medicare Advantage
- Products:
- P3 Care Model | P3 Senior Wellness Centers | P3 Care Access 24/7 | Care coordination services | Administrative services for providers
- Customers:
- Blue Cross and Blue Shield of Nebraska
[WEB-INTEL 2026-08-26] 9 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Value of $2.3 Billion With Over $180 Million in Cash to Fund Growth." [https://ir.p3hp.org/news-events/press-releases/detail/46/p3-health-partners-to-become-publicly-traded-via-merger] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The transaction is expected to result in gross proceeds of approximately $42.2 million, including approximately $20.0 million of gross proceeds from purchases" [https://ir.p3hp.org/news-events/press-releases/detail/106/p3-health-partners-inc-announces-approximately-42-2] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The total commitment provided by the Sponsor will total $900,000, none of which had been borrowed as of December 2, 2021." [https://ir.p3hp.org/sec-filings/all-sec-filings/xbrl_doc_only/2127] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "P3 Health Partners has raised a total of $42M of funding over 3 rounds. Their latest funding round was raised on May 23, 2024 in the amount of $42M." [https://leadiq.com/c/p3-health-partners/5a1dd8fe2300005e00e56aab] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "P3 Health Partners, Inc. receives financing of $70M in funding. P3 Health Partners obtained up to $70.0 million of funding via a Promissory Note from affiliate VBC Growth SPV 5, LLC, bearing 19.5% annual interest plus upfront and back-end f" [https://leadiq.com/c/p3-health-partners/5a1dd8fe2300005e00e56aab] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "P3 Health Partners, Inc. receives financing of $25M in financing. P3 Health Partners secures $25 million financing deal." [https://leadiq.com/c/p3-health-partners/5a1dd8fe2300005e00e56aab] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "On December 12, 2024, P3 Health Partners' subsidiary, P3 Health Group, LLC, secured up to $25 million through an unsecured promissory note with ..." [https://www.investing.com/news/sec-filings/p3-health-partners-secures-25-million-financing-deal-93CH-3778139] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "P3 Health Partners has raised funding over 2 rounds. Its first funding round was on Mar 31, 2023. Its latest funding round was a Post IPO round on May 23, 2024 for $*****." [https://tracxn.com/d/companies/p3-health-partners/__7zDKOeLxsjHSDtk6jDbHLEEXJ8vifSUKxQ_bJ_A3QIc] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "As of July 2026, P3 Health Partners has raised $332M in funding." [https://leadiq.com/c/p3-health-partners/5a1dd8fe2300005e00e56aab]
Source: https://p3hp.org/ · captured Aug 26, 2026 · marketing claims are reported as claims, never merged into the filed figures above.
The deal it’s entering
P3 Health Partners is merging with Foresight Acquisition Corp. (FORE) currently marked Closed (deSPAC).
| Headline equity value | — |
Structure per SEC accession(s) 0001193125-21-310439. How to read these numbers: headline vs effective valuation · what a definitive agreement commits
What exactly is being valued, and at what
Common questions
Is P3 Health Partners going public?
P3 Health Partners has an approved merger with the SPAC Foresight Acquisition Corp. (FORE). Deal status: Closed (deSPAC).
Does P3 Health Partners have revenue?
The filings we've parsed don't state a usable revenue figure yet; this profile is updated as new documents land.
Educational content, not investment advice.
- Oak Hill Bio — with RACC ($160M) · pre-revenue
- Longevity Biomedical — with FTII ($100M) · pre-revenue
- GNQ Insilico — with IBAC ($500M)
- HCC Healthcare Pte. — with RFAM ($500M)
- OmniAb — with AHPA
- Jasper Therapeutics — with AMHC